Public Sector Pension Investment Board Has $5.85 Million Holdings in Edwards Lifesciences Corporation $EW

Key Points

• The Public Sector Pension Investment Board increased its holdings in Edwards Lifesciences Corporation by 11.0%, acquiring an additional 7,998 shares, bringing its total ownership to 80,672 shares, valued at approximately $5,847,000.
• Multiple institutional investors made significant purchases in Edwards Lifesciences during the first quarter, with Nuveen LLC acquiring shares valued at approximately $330.88 million.
• Edwards Lifesciences reported earnings of $0.67 per share for the quarter, surpassing estimates and indicating an 11.9% year-over-year revenue growth to $1.53 billion.

Public Sector Pension Investment Board grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 11.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,672 shares of the medical research company's stock after buying an additional 7,998 shares during the quarter. Public Sector Pension Investment Board's holdings in Edwards Lifesciences were worth $5,847,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Vega Investment Solutions acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $27,000. Global X Japan Co. Ltd. increased its stake in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after purchasing an additional 216 shares during the last quarter. Tradewinds Capital Management LLC increased its stake in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after purchasing an additional 205 shares during the last quarter. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $29,000. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president owned 50,356 shares in the company, valued at approximately $3,897,554.40. The trade was a 4.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,584 shares of company stock worth $1,897,762 in the last quarter. Corporate insiders own 1.29% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EW. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Argus upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Finally, Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Stock Performance

EW traded down $0.2320 on Thursday, reaching $81.1580. The company had a trading volume of 7,505,132 shares, compared to its average volume of 4,825,853. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The stock has a market cap of $47.65 billion, a P/E ratio of 11.68, a P/E/G ratio of 3.93 and a beta of 1.08. The company's fifty day moving average is $77.45 and its 200 day moving average is $74.60. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the business earned $0.70 EPS. Edwards Lifesciences's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.